Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Aug 14, 2024

BUY
$0.26 - $0.42 $884,192 - $1.43 Million
3,400,739 New
3,400,739 $884,000
Q1 2024

May 15, 2024

SELL
$0.26 - $0.42 $333,679 - $539,020
-1,283,381 Reduced 27.4%
3,400,739 $884,000
Q4 2023

Aug 15, 2024

BUY
$0.26 - $0.8 $1.22 Million - $3.75 Million
4,684,120 New
4,684,120 $1.41 Million
Q4 2023

Feb 12, 2024

SELL
$0.26 - $0.8 $238,128 - $732,703
-915,879 Reduced 16.35%
4,684,120 $1.41 Million
Q3 2020

Nov 13, 2020

BUY
$4.57 - $6.48 $15.2 Million - $21.6 Million
3,333,333 Added 147.06%
5,599,999 $29 Million
Q4 2018

Feb 14, 2019

BUY
$13.0 - $22.57 $20.8 Million - $36.1 Million
1,600,000 Added 240.0%
2,266,666 $32.9 Million
Q2 2018

Aug 14, 2018

SELL
$19.0 - $29.84 $76 Million - $119 Million
-4,000,000 Reduced 85.71%
666,666 $12.7 Million
Q1 2018

May 15, 2018

BUY
$10.04 - $28.25 $46.9 Million - $132 Million
4,666,666 New
4,666,666 $88.3 Million

Others Institutions Holding NCNA

About NuCana plc


  • Ticker NCNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,196,000
  • Market Cap $148M
  • Description
  • NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...
More about NCNA
Track This Portfolio

Track Sofinnova Investments, Inc. Portfolio

Follow Sofinnova Investments, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sofinnova Investments, Inc. with notifications on news.